Joseph Catanzaro
Stock Analyst at Mizuho
(2.19)
# 2,892
Out of 5,043 analysts
101
Total ratings
38.1%
Success rate
-0.75%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Initiates: Outperform | $24 | $11.09 | +116.41% | 3 | Oct 21, 2025 | |
| RVMD Revolution Medicines | Initiates: Outperform | $90 | $54.48 | +65.20% | 3 | Oct 21, 2025 | |
| CLDX Celldex Therapeutics | Initiates: Outperform | $48 | $26.72 | +79.64% | 1 | Oct 21, 2025 | |
| APGE Apogee Therapeutics | Initiates: Outperform | $105 | $53.32 | +96.92% | 1 | Oct 21, 2025 | |
| KYMR Kymera Therapeutics | Initiates: Outperform | $81 | $58.56 | +38.32% | 1 | Oct 21, 2025 | |
| IBRX ImmunityBio | Upgrades: Overweight | $4.25 → $5 | $2.47 | +102.43% | 5 | May 20, 2025 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $2.5 → $5 | $3.26 | +53.37% | 5 | May 15, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Neutral | $7.5 → $6 | $2.25 | +166.67% | 10 | Feb 28, 2025 | |
| SDGR Schrödinger | Maintains: Overweight | $50 → $45 | $22.52 | +99.82% | 3 | Feb 27, 2025 | |
| MRUS Merus | Initiates: Overweight | $84 | $94.88 | -11.47% | 1 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $110 | $120.94 | -9.05% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $38 | $38.72 | -1.86% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $15.04 | -0.27% | 3 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $52 → $53 | $66.15 | -19.88% | 9 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $10 | $2.23 | +348.43% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $19 | $1.46 | +1,201.37% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $10.18 | +86.64% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $15 | $3.93 | +281.68% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 | $31.97 | +12.61% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 | $7.49 | +434.05% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $11.49 | +30.55% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $1.26 | +257.14% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $2.07 | +1,349.28% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.46 | +1,269.86% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $10 | $4.22 | +136.97% | 4 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $7.50 | +140.16% | 1 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $25 | $1.96 | +1,175.51% | 3 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $1.75 | $5.76 | -69.62% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $20.96 | -4.58% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $1.70 | -11.76% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $200 | $10.56 | +1,793.94% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $8.23 | +325.27% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.03 | +5,725.24% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $2.59 | +594.98% | 3 | Apr 7, 2020 |
Nurix Therapeutics
Oct 21, 2025
Initiates: Outperform
Price Target: $24
Current: $11.09
Upside: +116.41%
Revolution Medicines
Oct 21, 2025
Initiates: Outperform
Price Target: $90
Current: $54.48
Upside: +65.20%
Celldex Therapeutics
Oct 21, 2025
Initiates: Outperform
Price Target: $48
Current: $26.72
Upside: +79.64%
Apogee Therapeutics
Oct 21, 2025
Initiates: Outperform
Price Target: $105
Current: $53.32
Upside: +96.92%
Kymera Therapeutics
Oct 21, 2025
Initiates: Outperform
Price Target: $81
Current: $58.56
Upside: +38.32%
ImmunityBio
May 20, 2025
Upgrades: Overweight
Price Target: $4.25 → $5
Current: $2.47
Upside: +102.43%
CytomX Therapeutics
May 15, 2025
Maintains: Overweight
Price Target: $2.5 → $5
Current: $3.26
Upside: +53.37%
Iovance Biotherapeutics
Feb 28, 2025
Maintains: Neutral
Price Target: $7.5 → $6
Current: $2.25
Upside: +166.67%
Schrödinger
Feb 27, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $22.52
Upside: +99.82%
Merus
Feb 13, 2025
Initiates: Overweight
Price Target: $84
Current: $94.88
Upside: -11.47%
Feb 12, 2025
Maintains: Overweight
Price Target: $105 → $110
Current: $120.94
Upside: -9.05%
Feb 12, 2025
Maintains: Overweight
Price Target: $37 → $38
Current: $38.72
Upside: -1.86%
Jan 17, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $15.04
Upside: -0.27%
Jan 10, 2025
Maintains: Neutral
Price Target: $52 → $53
Current: $66.15
Upside: -19.88%
Dec 13, 2024
Maintains: Overweight
Price Target: $7 → $10
Current: $2.23
Upside: +348.43%
Oct 31, 2024
Maintains: Overweight
Price Target: $10 → $19
Current: $1.46
Upside: +1,201.37%
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $10.18
Upside: +86.64%
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $3.93
Upside: +281.68%
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $31.97
Upside: +12.61%
Jul 8, 2024
Maintains: Overweight
Price Target: $40
Current: $7.49
Upside: +434.05%
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $11.49
Upside: +30.55%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $1.26
Upside: +257.14%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $2.07
Upside: +1,349.28%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $1.46
Upside: +1,269.86%
Mar 18, 2024
Maintains: Overweight
Price Target: $15 → $10
Current: $4.22
Upside: +136.97%
Feb 12, 2024
Initiates: Overweight
Price Target: $18
Current: $7.50
Upside: +140.16%
Oct 16, 2023
Maintains: Overweight
Price Target: $30 → $25
Current: $1.96
Upside: +1,175.51%
May 23, 2023
Downgrades: Neutral
Price Target: $15 → $1.75
Current: $5.76
Upside: -69.62%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $20.96
Upside: -4.58%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $1.70
Upside: -11.76%
Mar 10, 2022
Maintains: Overweight
Price Target: $240 → $200
Current: $10.56
Upside: +1,793.94%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $8.23
Upside: +325.27%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $1.03
Upside: +5,725.24%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $2.59
Upside: +594.98%